PDX model details
| PDX ID | 224R Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
30 (12*) |
| Average PDX Generation Time (days +/- SEM) | 81 ± 5 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 224R Cx |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 224R Cx | ATM | 0.528 | 2.884 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | CHD1 | 1.018 | 4.050 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | CHD7 | 1.148 | 4.433 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | FANCD2 | -1.407 | 0.754 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | GEMIN5 | 0.749 | 3.362 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | KMT2A | 0.528 | 2.884 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | MGA | -1.435 | 0.739 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | MRE11A | 0.528 | 2.884 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | PTEN | -22.723 | 2.890e-07 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | SPEN | 0.742 | 3.345 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | TCERG1 | 0.749 | 3.362 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | U2AF1 | 0.828 | 3.550 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 224R Cx | USP28 | 0.528 | 2.884 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 224R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | Mixed Adeno & Neuro |
| Gleason Score | 9 |
| Primary Gleason Score | 4 |
| Secondary Gleason Score | 5 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 5 |
| Tumour Grade | pT3b |
| D'Amico Risk Classification | 7 |
| Tumour Volume (in cc) | 8.0 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 224 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 5.1 |
| Consent to share data | |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 224R |
| Patient Age (binned in 5 year age groups) | 60-64 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 224R Cx | TP53 | 311 | 1.0 | Missense variant | '8/11 | . | 21.1 | Likely pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 224R Cx | DOT1L | 433 | 0.52 | Missense variant | '26/28 | 4.06E-06 | 29.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 224R Cx | CRMP1 | 353 | 0.47 | Splice donor variant | . | . | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 224R Cx | HOXB13 | 385 | 0.39 | Missense variant | '2/2 | . | 27.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 224R Cx | FAM46C | 457 | 0.34 | Missense variant | '2/2 | 1.63E-05 | 24.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 224R Cx | GID4 | 442 | 0.33 | Missense variant | '3/6 | 1.22E-05 | 32 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 224R Cx | TP63 | 443 | 0.3 | Missense variant,splice region variant | '11/14 | 7.32E-05 | 16.64 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
This table displays drug response data
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
| PDX ID | Treatment1 | Dose (mg/kg) | Frequency | Treatment2 | Dose (mg/kg) | Frequency | Response |
|---|---|---|---|---|---|---|---|
| 224R Cx | Carboplatin | 50 | qwk | NA | NA | NA | Response |
| 224R Cx | Talazoparib | 0.33 | qd | Carboplatin | 50 | qwk | Response |
| 224R Cx | Talazoparib | 0.33 | qd | NA | NA | NA | Response |